Application of stromal vascular fraction cells and mesenchymal progenitor cells to prevention or treatment of osteoarthritis

An osteoarthritis, vascular layer technology, applied in the application field of interstitial vascular layer cells and mesenchymal progenitor cells in the prevention or treatment of osteoarthritis, can solve the lack of methods for prevention or treatment of knee osteoarthritis, Donor site destruction, inability to treat cartilage defects, etc.

Pending Publication Date: 2014-05-28
CELLULAR BIOMEDICINE GRP SHANGHAI
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, a major limitation of autologous chondrocyte transplantation or matrix-induced autologous chondrocyte transplantation is the inability to treat larger cartilage defects, the damage it causes to the donor site, dedifferentiation, and the limited survival time of chondrocytes, among other factors, Not suitable for KOA patients
[0007] It is precisely because of the strong immune rejection of allogeneic chondrocyte transplantation that there is currently no method for preventing or treating knee osteoarthritis in this field, so it is urgent to explore novel treatment and repair strategies

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of stromal vascular fraction cells and mesenchymal progenitor cells to prevention or treatment of osteoarthritis
  • Application of stromal vascular fraction cells and mesenchymal progenitor cells to prevention or treatment of osteoarthritis
  • Application of stromal vascular fraction cells and mesenchymal progenitor cells to prevention or treatment of osteoarthritis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0154] SVF and haMPCs for Knee Osteoarthritis (KOA)

example 1

[0156]The patient is a 45-year-old woman with bilateral knee joint pain for more than 3 years, morning stiffness, limited mobility, difficulty in going up and down stairs, and pain when walking on level ground. X-ray examination showed obvious osteophytes, joint space narrowing, and sclerotic changes . The WOMAC score is 92 points. Diagnosis: moderate knee osteoarthritis.

[0157] About 30ml of fat was extracted from the lower abdomen of KOA patients, and the vascular matrix part was separated from 10ml of freshly obtained adipose tissue, and the SVF was obtained after collagenase digestion, filtration, and centrifugation to remove mature adipocytes, and the surface antigen of the SVF was identified. For identification results, see figure 2 .

[0158] Dose each side as 5*10 6 Each cell / 2ml of SVF was injected into the bilateral joint cavity of the patient. The remaining adipose tissue was isolated and purified, and the P2-P5 generations were cultured to obtain haMPCs. T...

Embodiment 2

[0165] Identification of embodiment 2SVF and haMPCs

[0166] 1. Flow detection

[0167] Cells were collected into centrifuge tubes by enzymatic digestion, and the cell suspension was adjusted to a density of 1×10 5 / mL, 800r / min (120g), centrifuge for 5min, discard the supernatant, wash the resuspended cells with cold D-Hanks at 4°C, centrifuge the cell suspension again at 800r / min for 5min, and then discard the supernatant. Then the cells were resuspended to 1 mL with D-Hanks, 5-10 μL of antibody was added, protected from light, and placed on ice for 30 min. Rinse with D-Hanks, centrifuge, discard the supernatant, repeat the washing process 2-3 times to ensure that unbound antibodies are removed, and finally, add about 200 to 300 μL of D-Hanks to make a suspension, and use a flow cytometer to detect ( figure 2 ).

[0168] The flow cytometric detection results of SVF are shown in Table 1.

[0169] Table 1

[0170]

[0171] The expression of cell surface antigen marke...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to application of stromal vascular fraction cells and mesenchymal progenitor cells to the prevention or treatment of osteoarthritis. Specifically, remarkable prevention or treatment effects on osteoarthritis are achieved by applying a medicinal composition containing the stromal vascular fraction cells and the mesenchymal progenitor cells from autologous fat to an object with requirements. The mesenchymal progenitor cells have high cytokine secretion capability and the effect of repairing damage to organisms in a body. The stromal vascular fraction cells and the mesenchymal progenitor cells have chondrogenic differentiation and bone formation capability. The invention also provides the medicinal composition containing the stromal vascular fraction cells and the mesenchymal progenitor cells and a method for preventing and treating osteoarthritis.

Description

technical field [0001] The invention belongs to the field of stem cells and biomedicine. Specifically, the present invention relates to the application of interstitial vascular layer cells and mesenchymal progenitor cells in the prevention or treatment of osteoarthritis. Background technique [0002] Osteoarthritis (OA) is a chronic joint disease characterized by degeneration and destruction of articular cartilage and bone hyperplasia. OA affects up to 50% of people over the age of 60 and 80% of people over the age of 75. The disability rate of this disease can be as high as 53% (Orthopedic Branch of Chinese Medical Association, 2007 "Osteoarthritis Diagnosis and Treatment Guidelines" revised edition). OA is prone to occur in joints with heavy load and high activity, such as the knee joint, so it is called knee osteoarthritis (KOA). Knee osteoarthritis is a serious hazard to human health and is one of the main diseases that cause activity dysfunction in the elderly. [00...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/12A61P19/02A61P29/00A61K35/28A61K35/35
CPCA61K35/28A61K35/35A61P19/02A61P29/00C12N5/0652C12N5/0667A61K2300/00
Inventor 曹卫张丽卡尤姆周玉洁曾晓聆赵光宇关战军王新华
Owner CELLULAR BIOMEDICINE GRP SHANGHAI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap